Isunakinra

About Buzzard Pharmaceutical

Buzzard Pharmaceuticals is a Swedish biotech advancing isunakinra, a potent dual IL-1α/IL-1β inhibitor, for cancer. The company is building on promising Phase I data and is currently running a Phase 2A study in microsatellite stable, KRAS-mutated colorectal cancer, with plans to initiate a trial in neoadjuvant triple-negative breast cancer. Its strategy leverages the role of IL-1 as a master regulator of tumor-promoting inflammation and immunosuppression, aiming to enhance the efficacy of existing immunotherapies like PD-1 inhibitors.

About Buzzard Pharmaceutical

Buzzard Pharmaceuticals is a Swedish biotech advancing isunakinra, a potent dual IL-1α/IL-1β inhibitor, for cancer. The company is building on promising Phase I data and is currently running a Phase 2A study in microsatellite stable, KRAS-mutated colorectal cancer, with plans to initiate a trial in neoadjuvant triple-negative breast cancer. Its strategy leverages the role of IL-1 as a master regulator of tumor-promoting inflammation and immunosuppression, aiming to enhance the efficacy of existing immunotherapies like PD-1 inhibitors.

Therapeutic Areas